CancerDrs

Brain Cancer clinical trials in Alabama

13 actively recruiting brain cancer trials at 2 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Alabama:
  • University of Alabama — Birmingham, Alabama
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
Phase 2 Recruiting Academic/Other

Combination Therapy for the Treatment of Diffuse Midline Gliomas

This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…

Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Academic/Other

Digoxin Medulloblastoma Study

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Alabama:
  • University of Alabama at Birmingham Children's of Alabama — Birmingham, Alabama
Phase 2 Recruiting Academic/Other

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…

Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Academic/Other

Study of Pembrolizumab and M032 (NSC 733972)

This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the…

Sponsor: University of Alabama at Birmingham
NCT ID: NCT05084430
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Network

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…

Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
Phase 1 Recruiting Academic/Other

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK …

Sponsor: University of California, San Francisco
NCT ID: NCT04485559
Sites in Alabama:
  • University of Alabama at Birmingham, Children's of Alabama — Birmingham, Alabama
EARLY Phase 1 Recruiting Academic/Other

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (RT) with or without concurrent temozolom…

Sponsor: University of Alabama at Birmingham
NCT ID: NCT05632562
Sites in Alabama:
  • UAB — Birmingham, Alabama
  • UAB — Birmingham, Alabama
NA Recruiting Academic/Other

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of South Alabama — Mobile, Alabama
NA Recruiting Academic/Other

Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.

Sponsor: University of Alabama at Birmingham
NCT ID: NCT06857006
Sites in Alabama:
  • University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center — Birmingham, Alabama

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27